PMID- 34975600
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220104
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Electronic)
IS  - 1664-0640 (Linking)
VI  - 12
DP  - 2021
TI  - Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring 
      Substance Use Disorders: A Systematic Review.
PG  - 808002
LID - 10.3389/fpsyt.2021.808002 [doi]
LID - 808002
AB  - Objectives: Co-occurring substance use disorders (SUDs) among individuals with 
      schizophrenia are a prevalent and complex psychiatric comorbidity, which is 
      associated with increased symptom severity, worsened illness trajectory and high 
      rates of treatment non-adherence. Recent evidence suggests that the use of 
      long-acting injectable (LAI) antipsychotics may provide an effective treatment 
      option for individuals with this dual-diagnosis. Methods: A systematic review of 
      the literature was conducted using the databases PubMed, PsychInfo and Google 
      Scholar for English-language studies, investigating the use of LAIs in 
      co-occurring schizophrenia and substance use disorders (SCZ-SUDs). Results: Eight 
      reports [one case study (n = 1), one case series (n = 8), three open-label 
      retrospective studies (n = 75), and three randomized controlled trials (n = 273)] 
      investigated the use of LAI antipsychotics in 357 participants with SCZ-SUDs 
      [alcohol use disorder: 5 studies, n = 282; cocaine use disorder: 5 studies, n = 
      85; amphetamine use disorder: 1 study, n = 1; cannabis use disorder: 3 studies, n 
      = 160; opioid use disorder: 3 studies, n = 19; methylenedioxymethamphetamine 
      (MDMA) use disorder: 2 studies, n = 9; ketamine use disorder: 1 study, n = 4] and 
      were included in this systematic review. Findings indicate significant 
      improvements in substance use related outcomes across 7 of 8 studies, while in 6 
      of 8 studies, significant improvements in psychopathology-related outcomes were 
      reported. Conclusions: LAI antipsychotics may be an efficacious intervention 
      option for the treatment of SCZ-SUDs. However, varying methodological rigor, 
      generally small sample sizes and heterogeneity of samples, settings, substances 
      of abuse, tested LAIs and comparators, as well as psychosocial cotreatments and 
      level of reported detail across studies requires that these findings be 
      considered preliminary and interpreted with caution. Further research is required 
      to better understand the effects of LAIs among individuals with SCZ-SUDs.
CI  - Copyright (c) 2021 Coles, Knezevic, George, Correll, Kane and Castle.
FAU - Coles, Alexandria S
AU  - Coles AS
AD  - Centre for Complex Interventions, Centre for Addictions and Mental Health, 
      Toronto, ON, Canada.
FAU - Knezevic, Dunja
AU  - Knezevic D
AD  - Centre for Complex Interventions, Centre for Addictions and Mental Health, 
      Toronto, ON, Canada.
FAU - George, Tony P
AU  - George TP
AD  - Centre for Complex Interventions, Centre for Addictions and Mental Health, 
      Toronto, ON, Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
FAU - Correll, Christoph U
AU  - Correll CU
AD  - Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School 
      of Medicine at Hofstra/Northwell, Hempstead, NY, United States.
AD  - Department of Child and Adolescent Psychiatry, Charite Universitatsmedizin 
      Berlin, Berlin, Germany.
AD  - Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, United 
      States.
FAU - Kane, John M
AU  - Kane JM
AD  - Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School 
      of Medicine at Hofstra/Northwell, Hempstead, NY, United States.
AD  - Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, United 
      States.
FAU - Castle, David
AU  - Castle D
AD  - Centre for Complex Interventions, Centre for Addictions and Mental Health, 
      Toronto, ON, Canada.
AD  - Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
LA  - eng
PT  - Systematic Review
DEP - 20211215
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC8715086
OTO - NOTNLM
OT  - antipsychotic
OT  - long acting injectable (LAI)
OT  - schizophrenia
OT  - substance use disorder (SUD)
OT  - treatment
COIS- CC has been a consultant and/or advisor to or has received honoraria from: 
      AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Damitsa, Gedeon 
      Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J & J, Karuna, LB 
      Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi 
      Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Relmada, 
      Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, 
      Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. 
      He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Rovi, and 
      Teva. He has received grant support from Janssen and Takeda. He received 
      royalties from UpToDate and is also a stock option holder of LB Pharma. DC has 
      received grant monies for research from Eli Lilly, Janssen Cilag, Roche, 
      Allergen, Bristol-Myers Squibb, Pfizer, Lundbeck, Astra Zeneca, Hospira; Travel 
      Support and Honoraria for Talks and Consultancy from Eli Lilly, Bristol-Myers 
      Squibb, Astra Zeneca, Lundbeck, Janssen Cilag, Pfizer, Organon, Sanofi-Aventis, 
      Wyeth, Hospira, Servier, Seqirus; and is a current or past Advisory Board Member 
      for Lu AA21004: Lundbeck; Varenicline: Pfizer; Asenapine: Lundbeck; Aripiprazole 
      LAI: Lundbeck; Lisdexamfetamine: Shire; Lurasidone: Servier; Brexpiprazole: 
      Lundbeck; Treatment Resistant Depression: LivaNova; Cariprazine: Seqirus. He is a 
      founder of the Optimal Health Program OHP, currently operating as Optimal Health 
      Australia, which holds the IP for OHP; is part owner of Clarity Healthcare. The 
      remaining authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/01/04 06:00
MHDA- 2022/01/04 06:01
PMCR- 2021/12/15
CRDT- 2022/01/03 05:36
PHST- 2021/11/02 00:00 [received]
PHST- 2021/11/23 00:00 [accepted]
PHST- 2022/01/03 05:36 [entrez]
PHST- 2022/01/04 06:00 [pubmed]
PHST- 2022/01/04 06:01 [medline]
PHST- 2021/12/15 00:00 [pmc-release]
AID - 10.3389/fpsyt.2021.808002 [doi]
PST - epublish
SO  - Front Psychiatry. 2021 Dec 15;12:808002. doi: 10.3389/fpsyt.2021.808002. 
      eCollection 2021.